Increase Probability of Phase 3 Success in Oncology Trials

See how adaptive trial design can improve probability of phase 3 success in heterogeneous oncology populations

Late-stage oncology trials can fail when treatment effects are diluted across heterogeneous patient populations. In this short video, Marc Buyse explains how IDDI helped improve the probability of success in a phase 3 non-small cell lung cancer trial by using adaptive Bayesian trial design to reduce risk of treatment effect dilution across patient populations. 

This case study illustrates how adaptive trial design can help you:

  • Identify patient populations most likely to respond to treatment
  • Improve phase 3 decision-making using phase 2 insights
  • Increase trial efficiency without increasing sample size
  • Support more targeted and lower-risk development strategies

Explore Related Case Studies

Planning a phase 2 or phase 3 oncology trial?

Talk to our statistical experts about adaptive trial designs that improve development decisions and increase probability of success.

By submitting this form, you agree to receiving commercial electronic messages such as emails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any email communication from IDDI.